Randomized trial demonstrates clinical improvement with daily baricitinib in refractory rheumatoid arthritis, highlighting an effective therapeutic option after biologic failure.
In patients with rheumatoid arthritis and an inadequate response to biologic DMARDs, baricitinib at a daily dose of 4 mg was associated with clinical improvement at 12 weeks. (Funded by Eli Lilly and Incyte; ClinicalTrials.gov number, NCT01721044.).
No takes yet. Share an insight, caveat, or question.
Genovese et al. (2016) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: